Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.

Pharmacogenetics - 1 Oct 2000

Raimundo S, Fischer J, Eichelbaum M, Griese E U, Schwab M, Zanger U M

Abstract excerpt

A subgroup of 10-15% of Caucasians are termed phenotypical 'intermediate metabolizers' of drug substrates of CYP2D6 because they have severely impaired yet residual in-vivo function of this cytochrome P450. Genotyping based on the currently known CYP2D6 alleles does not predict this phenotype satisfactorily. A systematic sequencing strategy through 1.6 kb of the CYP2D6 5'-flanking sequence revealed six mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Primers

Share to Genotype

Share to Oxidation-Reduction

Share to Pedigree

Share to Phenotype

Share to Sparteine

Source

Identifiers

PMID: 11037799
DOI: 10.1097/00008571-200010000-00001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.PMID 11037799Read ↗

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.Semantic proximity Read ↗

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.Semantic proximity Read ↗

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Semantic proximity Read ↗

Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41.Semantic proximity Read ↗

An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.Semantic proximity Read ↗

A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.Semantic proximity Read ↗

A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.Semantic proximity Read ↗

CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.Semantic proximity Read ↗

"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.Semantic proximity Read ↗

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.Semantic proximity Read ↗

Pharmacogenetics: the molecular genetics of CYP2D6 dependent drug metabolism.Semantic proximity Read ↗

Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.